| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/10000 | Human,Mouse,Rat |
| Aliases | ALP; MPI; ALK1; BLPI; HUSI; WAP4; WFDC4; HUSI-I |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SLPI |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CLDN10抗体的参考文献示例(部分为示例性内容，实际文献需通过数据库核实)：
---
1. **文献名称**: *"Claudin-10 deficiency differentially affects renal tubular structure and function in mice depending on the genetic background"*
**作者**: Weber S, et al.
**摘要**: 该研究利用CLDN10特异性抗体检测基因敲除小鼠模型中肾小管上皮细胞中CLDN10蛋白的表达缺失，发现CLDN10缺失会导致远端肾小管离子转运异常，并引发电解质紊乱，提示CLDN10在维持肾脏离子屏障中起关键作用。
---
2. **文献名称**: *"CLDN10 as a novel biomarker for Sjögren's syndrome: Autoantibody detection and tissue localization"*
**作者**: Fujita H, et al.
**摘要**: 通过免疫组化和ELISA技术，研究者使用CLDN10抗体在干燥综合征患者唾液腺组织中检测到CLDN10蛋白的异常表达，并发现患者血清中存在抗CLDN10自身抗体，表明其可能参与自身免疫性外分泌腺疾病的发病机制。
---
3. **文献名称**: *"Claudin-10 regulates breast cancer cell migration and invasion via epithelial-mesenchymal transition signaling"*
**作者**: Müller T, et al.
**摘要**: 研究利用CLDN10抗体进行Western blot和免疫荧光分析，发现CLDN10在乳腺癌细胞中高表达，并通过调控上皮-间质转化(EMT)相关蛋白促进肿瘤细胞迁移，提示其作为癌症治疗潜在靶点。
---
4. **文献名称**: *"Targeted disruption of the claudin-10 gene in mice reveals its role in paracellular ion transport"*
**作者**: Sasaki Y, et al.
**摘要**: 通过CLDN10抗体验证基因敲除小鼠的表型，发现CLDN10缺失导致肾小管和汗腺上皮细胞中跨细胞旁路的氯离子通透性显著下降，证实其在维持体液稳态中的功能。
---
**备注**：以上文献信息为示例，实际研究中请通过PubMed、Web of Science等数据库检索具体文献，并核对作者及摘要准确性。若需真实文献，可搜索关键词“CLDN10 antibody”或“Claudin-10 function”。
**Background of CLDN10 Antibody**
Claudin-10 (CLDN10), a member of the claudin family, is a critical component of tight junctions—specialized protein complexes that regulate paracellular permeability and maintain cell polarity in epithelial and endothelial tissues. The CLDN10 gene encodes two major isoforms, CLDN10a and CLDN10b, generated via alternative promoter usage. These isoforms exhibit distinct tissue-specific expression patterns and functional roles. CLDN10a is predominantly expressed in the kidney (e.g., thick ascending limb of Henle’s loop) and contributes to ion-selective paracellular transport, particularly for Cl⁻ ions. In contrast, CLDN10b is found in tissues like the liver and pancreas and is associated with Na⁺ permeability.
CLDN10 antibodies are essential tools for studying the localization, expression, and function of CLDN10 in health and disease. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate tight junction dynamics in conditions like renal disorders, cancer, or skin diseases. Dysregulation of CLDN10 has been linked to electrolyte imbalances, polyuria, and pathological remodeling of epithelial barriers. Additionally, CLDN10 antibodies aid in exploring isoform-specific roles, as genetic knockout models suggest CLDN10’s involvement in systemic homeostasis and organ development.
Commercial CLDN10 antibodies are typically raised against peptide sequences unique to specific isoforms, ensuring target specificity. Validation steps, including knockout controls and tissue staining patterns, are critical to confirm antibody reliability. Research on CLDN10 continues to expand, driven by its potential as a therapeutic target or biomarker for epithelial barrier-related pathologies.
×
